The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals.
These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest preclinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 1,800 preclinical stage partnering deals announced since 2014 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.
Chapter 5 provides a review of preclinical stage deal making since 2014. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.
Chapter 6 provides a detailed analysis of preclinical stage payment terms including headline, upfront, milestone and royalty rates.
Chapter 7 provides a review of the leading preclinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 8 provides a comprehensive listing of the top 25 most active preclinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2014, where a contract document is available in the public domain.
Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2014.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2014.
In addition, a comprehensive appendix of all preclinical deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.
Key benefits Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 provides the reader with the following key benefits: In-depth understanding of preclinical stage deal trends since 2014 Access to headline, upfront, milestone and royalty data Analysis of the structure of preclinical stage agreements with numerous real life case studies Insight into the terms included in a preclinical stage agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 is intended to provide the reader with an in-depth understanding and access to preclinical stage deal trends and structure of deals entered into by leading companies worldwide.
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 includes: Trends in preclinical stage dealmaking in the biopharma industry since 2014 Analysis of preclinical stage deal structure Access to headline, upfront, milestone and royalty data Case studies of real-life preclinical stage deals Access to over 1,800 preclinical stage deals The leading preclinical stage deals by value since 2014 Most active preclinical stage dealmakers since 2014 The leading preclinical stage partnering resources
In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal type Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides comprehensive access to available deals and contract documents for over 1,800 preclinical stage deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are sale sand payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Gliosarcoma Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Gliosarcoma Global Clinical Trials Review, H2, 2020" provides an overview of Gliosarcoma Clinical trials scenario.This report provides top line data relating to the clinical trials on Gliosarcoma. Report includes...
Global Autoimmune Partnering 2014 to 2020 provides the full collection of Autoimmune disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Autoimmune partnering deals Financial deal terms for headline, upfront and royalty by stage of development Autoimmune partnering...
The global liquid biopsy market is expected to reach nearly US$ 8.2 Billion by 2027. Liquid biopsy is a non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. Liquid biopsy aids in planning the required treatment and also check for treatment effectiveness as well as...
C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2020 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report...
Global Medical Device Partnering Terms and Agreements 2014-2020 report provides a detailed understanding and analysis of how and why companies enter Medical Device partnering deals. This report provides details of the latest Medical Device agreements announced in the life sciences since 2014. The report takes...
The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2020 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest licensing...
The global single-use bioreactors market is projected to reach USD 3.9 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 18.0% during the forecast period. Increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in the cultivation of marine organisms, reduced energy and water consumption,...
Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2020, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape. Cancer...
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The report provides a detailed understanding and analysis of how and why companies enter business, product,...
Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020 Summary According to the recently published report ’Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020’; Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 220.127.116.11) pipeline Target constitutes close to 34 molecules. Out of which...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.